Rep. Joe Pitts (R-Penn.) is keeping a close eye on the FDA.
Following the successful House and Senate passage on the latest iteration of the FDA user fee reauthorization act, which increased the fees that medical device and drug makers pay for product review in exchange for meeting certain performance goals, Pitts isn’t about to let the agency slack.